Clinical trials: Treatment naïve
Obsessive-Compulsive Disorder
Pragmatic Trial of Obsessive-compulsive Disorder
This study includes a sequenced clinical trial in order to assess the efficacy of several switching or augment strategies when initial treatment is ineffective，and to provide strong evidence for clinical practice and…
- Trial name
- Proceed (NCT04539951)
- Testing
- Sertraline 200 milligram(mg), Sertraline 300 milligram(mg), Fluvoxamine
- Where
- China
- Volunteers
- 1,600 people
- Sponsor
- Shanghai Mental Health Center
Chronic Hepatitis C Infection
Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients
The primary objective of this protocol is to study the effect of the standard of care in hepatitis C (pegylated interferon and ribavirin) associated with therapeutic vaccine TG4040 on the viral load of treatment-naïve patients…
- Trial name
- HCVac (NCT01055821)
- Testing
- pegylated interferon and ribavirin, TG4040 + SOC
- Where
- Germany
- Volunteers
- 140 people
- Sponsor
- Transgene
HIV Infections
Immunological and Viral Response to Antiretrovirals in HIV Patients With CD4 Cell Count Below 100
The study analyzes the virological response in plasma and non-plasma compartments, as well as the degree and kinetics of immune reconstitution in 70 treatment-naive patients with CD4 < 100/mm3, when they receive treatment with…
- Trial name
- NCT00385957
- Testing
- AZT+3TC+IDV+RTV, AZT+3TC+EFV
- Where
- 6 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Hospital Clinic of Barcelona
Hepatitis C, Chronic
A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4
This equally randomized (1:1), double-blind, parallel arm study will assess the safety and antiviral efficacy of RO5024048 added to standard Pegasys (peginterferon alfa-2a) plus Copegus (ribavirin) therapy in patients with…
- Trial name
- NCT01057667
- Testing
- RO5024048, Ribavirin [Copegus], peginterferon alfa-2a [Pegasys]
- Where
- 25 sites in United States, Canada
- Volunteers
- 168 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C Infection
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
This is a phase 3, double-blinded, multicenter study. The study will consist of 2 substudies: Substudy 1 (SS1) will be double-blinded and enroll non-cirrhotic subjects and Substudy 2 (SS2) will be open label and enroll subjects…
- Trial name
- GIFT I (NCT02023099)
- Testing
- ABT-450/r/ABT-267
- Volunteers
- 363 people
- Sponsor
- AbbVie
Chronic HCV Infection
Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection
This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + ribavirin (RBV) in treatment-naive adults with chronic genotype 1 or 3 hepatitis C virus (HCV) infection.
- Trial name
- NCT02074514
- Testing
- Sofosbuvir, RBV
- Where
- 13 sites in India
- Volunteers
- 117 people
- Sponsor
- Gilead Sciences
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors
Impact of Pretreatment Emotional Distress on Survival and the Predictive Role of Peripheral Biomarkers in Immunotherapy Response Among Gastroesophageal and Lung Cancer Patients
This is the prospective, observational cohort study to explore the impact of pretreatment emotional distress on survival and the predictive role of peripheral blood metabolic and inflammatory markers in immunotherapy response…
- Conditions
- Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors, Inflammation, Cancer, Treatment-Related
- Trial name
- NCT06629714
- Testing
- Exposure: emotional distress status
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Anhui Medical University
Hepatitis C
Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection
This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir plus ribavirin administered for 16 weeks and 24 weeks in participants with chronic genotype 1 (GT1) or genotype 3 (GT3) hepatitis C virus…
- Trial name
- NCT01896193
- Testing
- SOF, RBV
- Where
- 16 sites in Russia
- Volunteers
- 127 people
- Sponsor
- Gilead Sciences
Growth Hormone Treatment
Three-times-weekly Versus Daily Growth Hormone (GH) Treatment in naïve GH-deficient Children
Growth hormone (GH) treatment in patients with GH deficiency (GHD) is commonly administered daily, although the pulsatile GH secretion is unlikely to be achieved and this regimen is often not complied.
- Trial name
- GH 3 wk dose (NCT03033121)
- Testing
- Growth Hormone
- Where
- Italy
- Volunteers
- 32 people
- Sponsor
- University of Palermo
Neoplasm Metastasis, Advanced Tumors
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
This is a study in adults with various types of advanced cancer. The purpose of the study is to test a medicine called BI 754091 in combination with several other cancer medicines. BI 754091 is an immunotherapy.
- Conditions
- Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors
- Trial name
- NCT03697304
- Testing
- Ezabenlimab, BI 754111, BI 836880
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 211 people
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis C Virus (HCV)
ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis
This is a Phase 3, open-label, multicenter study evaluating the efficacy and safety of ABT-450/r/ ABT-267 and ABT-333 coadministered with RBV for 12 weeks in HCV genotype 1b, treatment naïve and Interferon (IFN) (alpha, beta or…
- Trial name
- NCT02517528
- Testing
- ABT-450/r/ABT-267, ABT-333, ribavirin
- Volunteers
- 104 people
- Sponsor
- AbbVie
Multiple Myeloma
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
The purpose of this study is to compare the efficacy of lenalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of lenalidomide and low dose dexamethasone without pembrolizumab in terms of progression-free…
- Trial name
- NCT02579863
- Testing
- Pembrolizumab, Lenalidomide, Dexamethasone
- Volunteers
- 310 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Myelofibrosis, Secondary Myelofibrosis
Research Platform Myelofibrosis and Anemia
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor research platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of…
- Conditions
- Primary Myelofibrosis, Secondary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- RHODOLITE (NCT06976918)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- iOMEDICO AG
Hepatitis C, Hiv
Zepatier in Patients with Substance Use
The goal of this study is to assess hepatitis C virus (HCV) treatment with Zepatier (elbasvir/grazoprevir) in HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or…
- Conditions
- Hepatitis C, Hiv, Coinfection, HIV, Substance Use Disorders
- Trial name
- NCT04048850
- Testing
- Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Illinois Chicago
HIV Positive
Bone, Inflammation, Gut and Renal Biomarkers in Antiretroviral Naïve HIV-1 Positive Subjects
Co-morbidities, including low bone mineral density, increased visceral adiposity and chronic kidney disease (CKD) are frequent in people living with HIV, and may be driven by ongoing inflammation and immune activation.
- Trial name
- BIGGER (NCT03660722)
- Testing
- blood and urinary samples
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Carcinoma, Non-Small-Cell Lung
Real World Data on Gi(l)Otrif® Dose Adjustment
This is a non-interventional, multi-country, multi-site study based on existing data from medical records of patients treated with Gi(l)otrif® as part of the routine treatment according to the approved label.
- Trial name
- NCT02751879
- Where
- 29 sites in United States, Austria and 11 more
- Volunteers
- 228 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C, Chronic
Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection
Primary objectives: The purpose of this study is to determine and compare the sustained virologic response (SVR, undetectable HCV RNA at Follow up week 24 (FW24)) across treatment groups.
- Trial name
- NCT01587586
- Testing
- PEGASYS 180 µg Q1W, P1101 180 µg Q1W, 48 doses, P1101 270µg Q1W, 48 doses
- Where
- 13 sites in Taiwan
- Volunteers
- 107 people
- Sponsor
- PharmaEssentia
Diabetes Mellitus, Type 2
Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)
The primary objective of this study is to compare the percentage of subjects who reach the target HbA1c level (< or = 7.0% at endpoint) and do not experience symptomatic nocturnal hypoglycemia during treatment with insulin…
- Trial name
- NCT00653341
- Testing
- insulin glargine, NPH human insulin
- Where
- 2 sites in United States, Canada
- Volunteers
- 764 people
- Sponsor
- Sanofi
Systemic Juvenile Idiopathic Arthritis
An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.
This open-label extension study will permit patients with Systemic Juvenile Idiopathic Arthritis (SJIA) who previously were responsive to treatment with canakinumab and canakinumab treatment-naïve patients with active SJIA with…
- Trial name
- β-SPECIFIC 3 (NCT00891046)
- Testing
- Canakinumab
- Where
- 73 sites in United States, Argentina and 19 more
- Volunteers
- 270 people
- Sponsor
- Novartis Pharmaceuticals
Extensive Small Cell Lung Cancer
A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer
Small cell lung cancer (SCLC) accounts for 15% of lung cancer cases and is an aggressive cancer characterized by rapid growth, early metastasis, and a poor prognosis.
- Trial name
- NCT06406673
- Testing
- Cadonilimab+EC/ET+RT, Cadonilimab+vorolanib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Henan Cancer Hospital